Law360, New York (August 17, 2007, 12:00 AM EDT) -- In the wake of a June ruling that AstraZeneca, Bristol-Myers Squibb and Schering-Plough Corp. inflated average wholesale prices of drugs, plaintiffs have asked the court to decide whether to grant treble damages and attorneys' fees before entering a final judgment.
The pharmaceutical companies had asked on August 10 that final judgment be rendered posthaste, saying that when Judge Patti B. Saris makes her final determination on damages, “the matter will be ripe for appeal.”
However, the plaintiffs have said that the judge must not only determine...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.